RANKL–RANK signaling in osteoclastogenesis and bone disease

Theill, 2002, RANK-L and RANK: T cells, bone loss, and mammalian evolution, Annu. Rev. Immunol., 20, 795, 10.1146/annurev.immunol.20.100301.064753

Boyle, 2003, Osteoclast differentiation and activation, Nature, 423, 337, 10.1038/nature01658

Karsenty, 2002, Reaching a genetic and molecular understanding of skeletal development, Dev. Cell, 2, 389, 10.1016/S1534-5807(02)00157-0

Wronski, 1983, Alterations in calcium homeostasis and bone during actual and simulated space flight, Med. Sci. Sports Exerc., 15, 410, 10.1249/00005768-198315050-00012

Anderson, 1997, A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function, Nature, 390, 175, 10.1038/36593

Wong, 1997, TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells, J. Biol. Chem., 272, 25190, 10.1074/jbc.272.40.25190

Yasuda, 1998, Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL, Proc. Natl. Acad. Sci. U. S. A., 95, 3597, 10.1073/pnas.95.7.3597

Yasuda, 1998, Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro, Endocrinology, 139, 1329, 10.1210/en.139.3.1329

Tsuda, 1997, Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis, Biochem. Biophys. Res. Commun., 234, 137, 10.1006/bbrc.1997.6603

Simonet, 1997, Osteoprotegerin: a novel secreted protein involved in the regulation of bone density, Cell, 89, 309, 10.1016/S0092-8674(00)80209-3

Fata, 2000, The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development, Cell, 103, 41, 10.1016/S0092-8674(00)00103-3

Ikeda, 2001, Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus, Endocrinology, 142, 1419, 10.1210/en.142.4.1419

Kong, 1999, Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand, Nature, 402, 304, 10.1038/46303

Horwood, 1999, Activated T lymphocytes support osteoclast formation in vitro, Biochem. Biophys. Res. Commun., 265, 144, 10.1006/bbrc.1999.1623

Wittrant, 2004, RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis, Biochim. Biophys. Acta, 1704, 49

Hsu, 1999, Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand, Proc. Natl. Acad. Sci. U. S. A., 96, 3540, 10.1073/pnas.96.7.3540

Kim, 2000, Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene, Proc. Natl. Acad. Sci. U. S. A., 97, 10905, 10.1073/pnas.200294797

Dougall, 1999, RANK is essential for osteoclast and lymph node development, Genes Dev., 13, 2412, 10.1101/gad.13.18.2412

Li, 2000, RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism, Proc. Natl. Acad. Sci. U. S. A., 97, 1566, 10.1073/pnas.97.4.1566

Kong, 1999, OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis, Nature, 397, 315, 10.1038/16852

Mizuno, 1998, Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin, Biochem. Biophys. Res. Commun., 247, 610, 10.1006/bbrc.1998.8697

Bucay, 1998, osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification, Genes Dev., 12, 1260, 10.1101/gad.12.9.1260

Hughes, 2000, Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis, Nat. Genet., 24, 45, 10.1038/71667

Whyte, 2002, Osteoprotegerin deficiency and juvenile Paget's disease, N. Engl. J. Med., 347, 175, 10.1056/NEJMoa013096

Cundy, 2002, A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype, Hum. Mol. Genet., 11, 2119, 10.1093/hmg/11.18.2119

Eriksson, 2003, Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity, Nat. Med., 9, 1484, 10.1038/nm960

Seshasayee, 2004, A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response, J. Biol. Chem., 279, 30202, 10.1074/jbc.M403968200

Suda, 2003, Vitamin D and bone, J. Cell. Biochem., 88, 259, 10.1002/jcb.10331

Walsh, 2003, Biology of the TRANCE axis, Cytokine Growth Factor Rev., 14, 251, 10.1016/S1359-6101(03)00027-3

Nakashima, 2000, Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines, Biochem. Biophys. Res. Commun., 275, 768, 10.1006/bbrc.2000.3379

Lynch, 2005, MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL, Cancer Cell, 7, 485, 10.1016/j.ccr.2005.04.013

Schlondorff, 2001, Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertase, J. Biol. Chem., 276, 14665, 10.1074/jbc.M010741200

Chesneau, 2003, Catalytic properties of ADAM19, J. Biol. Chem., 278, 22331, 10.1074/jbc.M302781200

Weber, 1994, Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy, Nat. Genet., 8, 352, 10.1038/ng1294-352

Lomaga, 1999, TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling, Genes Dev., 13, 1015, 10.1101/gad.13.8.1015

Iotsova, 1997, Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2, Nat. Med., 3, 1285, 10.1038/nm1197-1285

Ruocco, 2005, I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss, J. Exp. Med., 201, 1677, 10.1084/jem.20042081

Doffinger, 2001, X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling, Nat. Genet., 27, 277, 10.1038/85837

Wada, 2004, Mitogen-activated protein kinases in apoptosis regulation, Oncogene, 23, 2838, 10.1038/sj.onc.1207556

Chang, 2001, Mammalian MAP kinase signalling cascades, Nature, 410, 37, 10.1038/35065000

Matsumoto, 2000, Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL), J. Biol. Chem., 275, 31155, 10.1074/jbc.M001229200

Kwak, 2005, Monokine induced by interferon-gamma is induced by receptor activator of nuclear factor kappa B ligand and is involved in osteoclast adhesion and migration, Blood, 105, 2963, 10.1182/blood-2004-07-2534

David, 2002, JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms, J. Cell Sci., 115, 4317, 10.1242/jcs.00082

Yamamoto, 2002, Possible involvement of IkappaB kinase 2 and MKK7 in osteoclastogenesis induced by receptor activator of nuclear factor kappaB ligand, J. Bone Miner. Res., 17, 612, 10.1359/jbmr.2002.17.4.612

Kenner, 2004, Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects, J. Cell Biol., 164, 613, 10.1083/jcb.200308155

Wagner, 2002, Functions of AP1 (Fos/Jun) in bone development, Ann. Rheum. Dis., 61, ii40, 10.1136/ard.61.suppl_2.ii40

Hotokezaka, 2002, U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells, J. Biol. Chem., 277, 47366, 10.1074/jbc.M208284200

Takayanagi, 2002, Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts, Dev. Cell, 3, 889, 10.1016/S1534-5807(02)00369-6

Matsuo, 2004, Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos, J. Biol. Chem., 279, 26475, 10.1074/jbc.M313973200

Koga, 2005, NFAT and Osterix cooperatively regulate bone formation, Nat. Med., 11, 880, 10.1038/nm1270

Soriano, 1991, Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice, Cell, 64, 693, 10.1016/0092-8674(91)90499-O

Miyazaki, 2004, Src kinase activity is essential for osteoclast function, J. Biol. Chem., 279, 17660, 10.1074/jbc.M311032200

Koga, 2005, Physical and functional association of c-Src and adhesion and degranulation-promoting adaptor protein (ADAP) in osteoclastogenesis in vitro, J. Biol. Chem., 280, 31564, 10.1074/jbc.M502703200

Darnay, 1998, Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase, J. Biol. Chem., 273, 20551, 10.1074/jbc.273.32.20551

Mizukami, 2002, Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6, Mol. Cell. Biol., 22, 992, 10.1128/MCB.22.4.992-1000.2002

Hauer, 2005, TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-kappaB pathway by TRAF-binding TNFRs, Proc. Natl. Acad. Sci. U. S. A., 102, 2874, 10.1073/pnas.0500187102

Kanazawa, 2005, TRAF2 is essential for TNF-alpha-induced osteoclastogenesis, J. Bone Miner. Res., 20, 840, 10.1359/JBMR.041225

Kanazawa, 2003, TRAF5 functions in both RANKL- and TNFalpha-induced osteoclastogenesis, J. Bone Miner. Res., 18, 443, 10.1359/jbmr.2003.18.3.443

Wada, 2005, The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis, Nat. Med., 11, 394, 10.1038/nm1203

Vanhaesebroeck, 2000, The PI3K-PDK1 connection: more than just a road to PKB, Biochem. J., 346, 561, 10.1042/0264-6021:3460561

Nakamura, 1995, Wortmannin, a specific inhibitor of phosphatidylinositol-3 kinase, blocks osteoclastic bone resorption, FEBS Lett., 361, 79, 10.1016/0014-5793(95)00153-Z

Sugatani, 2003, PTEN regulates RANKL- and osteopontin-stimulated signal transduction during osteoclast differentiation and cell motility, J. Biol. Chem., 278, 5001, 10.1074/jbc.M209299200

Fackenthal, 2001, Male breast cancer in Cowden syndrome patients with germline PTEN mutations, J. Med. Genet., 38, 159, 10.1136/jmg.38.3.159

Takeshita, 2002, SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts, Nat. Med., 8, 943, 10.1038/nm752

Komarova, 2003, RANK ligand-induced elevation of cytosolic Ca2+ accelerates nuclear translocation of nuclear factor kappa B in osteoclasts, J. Biol. Chem., 278, 8286, 10.1074/jbc.M206421200

Takayanagi, 2005, Mechanistic insight into osteoclast differentiation in osteoimmunology, J. Mol. Med., 83, 170, 10.1007/s00109-004-0612-6

Duran, 2004, The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis, Dev. Cell, 6, 303, 10.1016/S1534-5807(03)00403-9

Laurin, 2002, Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone, Am. J. Hum. Genet., 70, 1582, 10.1086/340731

Hashimoto, 2005, PKClambda regulates glucose-induced insulin secretion through modulation of gene expression in pancreatic beta cells, J. Clin. Invest., 115, 138, 10.1172/JCI22232

Takayanagi, 2000, T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma, Nature, 408, 600, 10.1038/35046102

Fakruddin, 2003, HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk, J. Biol. Chem., 278, 48251, 10.1074/jbc.M304676200

Takayanagi, 2002, RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta, Nature, 416, 744, 10.1038/416744a

Syed, 2005, Mechanisms of sex steroid effects on bone, Biochem. Biophys. Res. Commun., 328, 688, 10.1016/j.bbrc.2004.11.097

Maini, 1995, Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease, Immunol. Rev., 144, 195, 10.1111/j.1600-065X.1995.tb00070.x

Candeliere, 1995, Increased expression of the c-fos proto-oncogene in bone from patients with fibrous dysplasia, N. Engl. J. Med., 332, 1546, 10.1056/NEJM199506083322304

Rahman, 2003, Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages, Blood, 101, 3451, 10.1182/blood-2002-08-2622

Kostenuik, 2005, Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength, Curr. Opin. Pharmacol., 5, 618, 10.1016/j.coph.2005.06.005

Valverde, 2004, Selective blockade of voltage-gated potassium channels reduces inflammatory bone resorption in experimental periodontal disease, J. Bone Miner. Res., 19, 155, 10.1359/jbmr.0301213